Filament Health

Today, @TheraPsil alongside @SabiMind and @FilamentHealth launched the first wellness-focused & stakeholder-funded psilocybin clinical trial. Psychedelic research is about to change. See full release here: therapsil.ca/press-psilwell…

.@FilamentHealth has received FDA approval for another clinical trial on its lead drug candidate PEX010. $FLHLF #psilocybin #Veterans #psychedelics mugglehead.com/fda-gives-anot…

Today we announced positive data from a phase 2 study of PEX010 in patients with alcohol use disorder. The study found that after 1 dose of #psilocybin, the mean % of heavy drinking days was reduced by more than 50% over the 12-week observation period. filament.health/news/filament-…

.@benlightburn @FilamentHealth discusses the company’s approach to psychedelic medicine, the case for natural botanical extracts rather than synthetic compounds, and its lead experimental therapy that targets methamphetamine use disorder. thebioreport.podbean.com/e/extracting-t…

Today we announced the import of Peruvian coca leaf to our Vancouver R&D facility for the development of a botanical drug candidate to treat ADHD. filament.health/news/filament-…

We're proud to supply our botanical psilocybin drug candidate for this much-needed research into opioid use disorder at @imperialcollege.

Today we announced a major expansion of our IP portfolio, with 12 new patents accepted in Australia, 5 in Canada, & 3 in the US. Filament holds a total of 46 allowed patents relating to the development & delivery of naturally-derived psychedelic APIs. filament.health/news/filament-…

Today we announced authorization by both @US_FDA & @GovCanHealth of a Phase 2 clinical trial studying PEX010 for methamphetamine use disorder. This is the first ever clinical trial to study the safety & efficacy of botanical #psilocybin for MAUD. filament.health/news/filament-…

We're pleased to report our Q1 2024 results, including important advancement of our drug development efforts in substance use disorders. filament.health/news/filament-…

Our CEO @benlightburn will be hosting an #AMA with @ceodotca at 12PM ET tomorrow to discuss our latest news and developments. Submit questions for Ben via: @ceoca_james" target="_blank" rel="nofollow noopener">ceo.ca/@ceoca_james

We're pleased to report our 2023 year-end results including $2.1 million in revenue + @GovCanHealth approval of a Filament-sponsored Phase 2 clinical trial studying our botanical psilocybin for opioid use disorder at @UBC. filament.health/news/filament-…

We're pleased to announce that Michael Messinger has been appointed to our Board of Directors, bringing over 20 years' experience in biotech finance roles. filament.health/news/filament-…

Join Robert Sassoon for a fireside chat with @FilamentHealth CEO Ben Lightburn on Thursday, April 4th, at 12:00 pm ET. #psychedelics #psychedelictherapy #therapeutics us06web.zoom.us/webinar/regist…

Read about @UCalgary's upcoming study which will examine the effects of our botanical #psilocybin for alcohol use disorder:

The @UCalgary is about to start a major study on psilocybin-assisted therapy for the treatment of alcoholism. British Columbia’s @FilamentHealth will provide magic mushroom extract needed for the research. $FLHLF #psychedelics #psilocybin mugglehead.com/alberta-univer…

We're proud to supply our botanical psilocybin for this important research at @UCalgary:

Today we announced that we have shipped our botanical psilocybin drug candidate, PEX010, to 4 countries for clinical trials at leading research institutions including @JohnsHopkins. filament.health/news/filament-…

Could psilocybin offer a solution to the opioid crisis? We take a look in our latest blog post: filament.health/news/psychedel…

2024 is set to be a watershed year for #Psychedelics. Alongside an influx of biotech investment in the UK, the industry has seen significant milestones set to accelerate the sector, return confidence & advance #MentalHealth innovations. Find out more. 👇 psychedelichealth.co.uk/2024/03/13/psy…

"We developed specific technology that has allowed us to create the first & only pharmaceutical grade natural psychedelic drug candidates." - CEO @benlightburn spoke to @PharmExec Magazine about our novel approach to psychedelic drug development. pharmexec.com/view/business-…